Cyclerion Therapeutics, Inc. (CYCN)
23.52
-6.23 (-20.94%)
Inactive · Last trade price on Sep 8, 2026
Cyclerion Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1.39 | 3.24 | 3.23 | 7.57 | 13.38 | 53.96 |
Cash & Short-Term Investments | 1.39 | 3.24 | 3.23 | 7.57 | 13.38 | 53.96 |
Cash Growth | -53.73% | 0.25% | -57.31% | -43.42% | -75.20% | -0.80% |
Receivables | - | 1 | 0.56 | - | 0.1 | 0.1 |
Prepaid Expenses | 0.11 | 0.38 | 0.42 | 0.44 | 0.81 | 0.93 |
Other Current Assets | 0.01 | 0.01 | 0.02 | 0.01 | 0.54 | 0.47 |
Total Current Assets | 1.51 | 4.64 | 4.23 | 8.02 | 14.82 | 55.46 |
Property, Plant & Equipment | 0.07 | - | - | - | 1.22 | 1.47 |
Long-Term Investments | 5.35 | 5.35 | 5.35 | 5.35 | - | - |
Other Long-Term Assets | - | - | - | - | 2.04 | 2.41 |
Total Assets | 6.93 | 9.99 | 9.58 | 13.37 | 18.08 | 59.33 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.6 | 0.51 | 0.39 | 1.2 | 2.97 | 1.83 |
Accrued Expenses | 0.18 | 0.35 | 0.31 | 0.78 | 4.59 | 8.73 |
Other Current Liabilities | 0.06 | 0.04 | 0.03 | 0.11 | 0.07 | 0.53 |
Total Current Liabilities | 1.84 | 0.9 | 0.73 | 2.09 | 7.63 | 11.09 |
Total Liabilities | 1.84 | 0.9 | 0.73 | 2.09 | 7.63 | 11.09 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Additional Paid-In Capital | 281.04 | 280.11 | 276.34 | 275.72 | 269.63 | 263.35 |
Retained Earnings | -275.95 | -271.02 | -267.49 | -264.42 | -259.15 | -215.08 |
Comprehensive Income & Other | - | - | - | -0.01 | -0.02 | -0.02 |
Shareholders' Equity | 5.09 | 9.09 | 8.85 | 11.29 | 10.45 | 48.25 |
Total Liabilities & Equity | 6.93 | 9.99 | 9.58 | 13.37 | 18.08 | 59.33 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash (Debt) | 1.39 | 3.24 | 3.23 | 7.57 | 13.38 | 53.96 |
Net Cash Growth | -53.73% | 0.25% | -57.31% | -43.42% | -75.20% | 523.11% |
Net Cash Per Share | 0.36 | 1.02 | 1.28 | 3.24 | 6.16 | 27.57 |
Filing Date Shares Outstanding | 4.61 | 4.23 | 2.55 | 2.54 | 2.18 | 2.17 |
Total Common Shares Outstanding | 4.26 | 3.82 | 2.55 | 2.47 | 2.18 | 2.17 |
Working Capital | -0.33 | 3.74 | 3.5 | 5.94 | 7.19 | 44.37 |
Book Value Per Share | 1.20 | 2.38 | 3.48 | 4.56 | 4.80 | 22.23 |
Tangible Book Value | 5.09 | 9.09 | 8.85 | 11.29 | 10.45 | 48.25 |
Tangible Book Value Per Share | 1.20 | 2.38 | 3.48 | 4.56 | 4.80 | 22.23 |
Machinery | - | - | - | - | - | 0.05 |